Exposure to proton pump inhibitors is associated with the development of pediatric autoimmune diseases
Proton pump inhibitors (PPIs) have been associated with decreased gut microbiota diversity. Disrupted gut microbiota composition has been reported in several autoimmune diseases (ADs), such as type 1 diabetes mellitus (DM), autoimmune thyroiditis (AIT), juvenile idiopathic arthritis (JIA), and infla...
Saved in:
Main Authors: | Laura Räisänen (Author), Heli Viljakainen (Author), Kaija-Leena Kolho (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Therapeutic Drug Monitoring and Outcome of Infliximab Therapy in Pediatric Onset Inflammatory Bowel Disease
by: Kaija-Leena Kolho, et al.
Published: (2021) -
Proton pump inhibitors in pediatric practice
by: Anna A. Shilova, et al.
Published: (2023) -
Disease control and psychiatric comorbidity among adolescents with chronic medical conditions: a single-centre retrospective study
by: Kaija-Leena Kolho, et al.
Published: (2023) -
Proton-pump inhibitors and risk of renal disease
by: Mahrang Hedaiaty, et al.
Published: (2017) -
Is hypomagnesemia associated with using proton pump inhibitors?
by: Joo-Hark Yi, et al.
Published: (2016)